Pioneering AI Drug Discovery

AI platform accelerating drug discovery by decoding biology with machine learning and high-throughput experiments.

Coding & Development AI Models & APIsPaid

Visit website ↗

$18Starting price

57KMonthly visits

29Popularity

Pioneering AI Drug Discovery featured image

About Pioneering AI Drug Discovery

Recursion’s platform combines large-scale biological datasets with advanced AI models to decode complex biological systems. The system integrates wet-lab experimentation with computational predictions, enabling rapid hypothesis generation and validation for drug discovery programs. Researchers and biotech teams use the platform to identify novel targets, optimize compounds, and prioritize candidates for preclinical development. By automating data collection and analysis, the tool reduces timelines and costs associated with traditional drug discovery workflows. The platform is designed for pharmaceutical companies, academic researchers, and biotech startups seeking scalable, data-driven approaches to therapeutic innovation. Recursion emphasizes collaboration and open science, offering tools that can be customized for specific disease areas or research questions. Its foundation model, fine-tuned on biological and chemical data, powers predictive capabilities across multiple stages of the drug discovery pipeline.

Recursion Pharmaceuticals

Salt Lake City, United States · Founded 2013

Founded: 2013
Headquarters: Salt Lake City, United States

Key features

Large-scale biological data integration
AI-driven target identification
Compound optimization and prioritization
High-throughput experimental automation
Predictive modeling for drug efficacy and safety
Customizable workflows for disease-specific research
Collaborative research environment
Foundation model fine-tuned on biological and chemical data
Automated data collection and analysis
Scalable platform for preclinical drug discovery

Use cases

Accelerating early-stage drug discovery for rare diseases
Optimizing lead compounds for therapeutic efficacy and safety
Identifying novel biological targets for undruggable diseases

Pros

Combines large-scale biological datasets with advanced AI models for drug discovery
Integrates wet-lab experimentation with computational predictions in a unified platform
Reduces timelines and costs associated with traditional drug discovery workflows
Operates a proprietary dataset exceeding 50 petabytes, enabling robust predictive capabilities
Supports end-to-end drug discovery from hit identification to IND-enabling studies

Cons

Requires significant computational and biological data infrastructure to operate effectively
May involve complex integration challenges for teams without prior AI or wet-lab automation experience
Dependent on the quality and scale of proprietary biological datasets for optimal performance

Pioneering AI Drug Discovery videos

Frequently asked questions about Pioneering AI Drug Discovery

What does Recursion’s AI drug discovery platform do?

Recursion’s platform uses AI to decode complex biological systems by analyzing cell images and other data, enabling rapid hypothesis generation and validation for drug discovery. It integrates wet-lab experimentation with computational predictions to identify novel drug targets and optimize compounds.

Who is Recursion’s platform designed for?

The platform is designed for pharmaceutical companies, academic researchers, and biotech startups seeking scalable, data-driven approaches to therapeutic innovation. It supports collaboration across disease areas and research questions.

How does Recursion’s platform integrate wet-lab and AI workflows?

Recursion operates an automated 'lab-in-the-loop' system where physical automation and machine learning models continuously learn from experiments. This creates a feedback loop between wet-lab data and AI predictions, improving drug discovery efficiency.

What types of diseases does Recursion focus on?

Recursion’s pipeline includes programs targeting oncology (solid tumors, lymphomas, and hematologic cancers), rare diseases (e.g., familial adenomatous polyposis, hypophosphatasia), and other high-unmet-need conditions.

Does Recursion offer partnerships or collaborations?

Yes, Recursion partners with pharmaceutical companies, technology providers, and data partners to accelerate drug discovery and expand its impact. These collaborations enhance its generative AI capabilities and clinical translation.

How can I get started with Recursion’s platform?

Prospective users can explore partnerships or collaborations by contacting Recursion through their website. The company offers tools and platforms that can be customized for specific research needs and disease areas.